Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses how the pandemic changed clinical trial enrollment in the leukemia/lymphoma space.
Lee Greenberger, PhD, chief scientific officer of the Leukemia and Lymphoma Society, discusses the COVID-19 pandemic's impact on clinical trial enrollment and the importance of open communication between patients participating in trials and their physicians.
Transcript
From your vantage point, is the pandemic still affecting clinical trial enrollment? What strategies have been effective for keeping trials going?
We definitely saw an impact on trial enrollment during COVID. Many of the clinicians told us about that. There's multiple reasons: Patients were afraid to come in, and the staff to do the work, they were either getting infected [or] they were not coming in. So, it definitely had an impact.
What we have seen is actually that enrollment has come back up, and I think that the NCI [National Cancer Institute] has actually reported on that as well—that, in general, clinical trial enrollment has come back up. Physicians and clinics have learned to deal with it, and I don't think that patients should be as concerned.
That being said, patients need to report if they get an infection to their physician on a clinical trial. As I said, there are steps that can be taken within the first 5 days. Patients should not hesitate to contact their physician if they're on a clinical trial and in the event that they get COVID.
New Insights Into Meth-Associated PAH Care Gaps: Anjali Vaidya, MD, on Closing the Divide
June 4th 2025Research from Anjali Vaidya, MD, FACC, FASE, FACP, Temple University Hospital, reveals critical care gaps for patients with methamphetamine-associated pulmonary arterial hypertension (PAH), emphasizing the need for early diagnosis and integrated support.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD
April 25th 2025When it comes to treating multiple myeloma (MM), Ajai Chari, MD, argued that more is not always better. More intense treatment regimens, or those with more drugs, don't necessarily guarantee better outcomes.
Read More
What's at Stake as Oral Arguments Are Presented in the Braidwood Case? Q&A With Richard Hughes IV
April 21st 2025Richard Hughes IV, JD, MPH, spoke about the upcoming oral arguments to be presented to the Supreme Court regarding the Braidwood case, which would determine how preventive services are guaranteed insurance coverage.
Read More